User Name Password

back to homepage

Sofame Technologies (SDW.V) - more detail on funding plans

Comment by Objective Capital , Sep 11, 2009
Click for previous reports on this company
Questions? Contact our analyst

On 10 September 2009, the company provided details of four new Manufacturer’s Representatives added to its sales organization, some operational detail and further information on its financing intentions.

The new territories with representatives in parentheses are: Washington DC, Virginia (Energy Advanced); Southern New York State (Accardi Companies); Connecticut (Analytics & Combustion Services); and Kansas, Iowa and Missouri (Hughes Machinery & Equipment).

Management notes that the rep training programme has been enhanced and that the three day programme in August with Canromex, its new Mexican rep, was a success.

Sofame also disclosed that it had “approved a private placement of equity securities up to C$2m Canadian Dollars to accredited investors resident in Canada and elsewhere”. This is in addition to the debt financing agreement with Township Capital previously announced for a like C$2m.

The press release goes on to state that Sofame is involved in discussions with several potential lenders and investors concerning the funding of sales and marketing initiatives as well as the working capital required for growth and continuing operations.

Objective's view:

The raising of sufficient working capital is Sofame’s most pressing corporate issue. Institutional investors, or conceivably a trade partner, might be interested in taking a stake in an enlarged business and this could solve Sofame’s financing impasse.

With a share price currently at around C$0.065 and an equity capitalization of C$6.5m, the likely pro-forma effects on share capital, estimated book value and earnings, should a further C$2m additional share capital be raised at this level would: Effect on share capital
Assuming C$2m is raised at C$0.065 per share (ignoring costs), this would involve issuing 30.8m new Sofame shares and increase the basic issued share capital from 99.9m shares, to 130.7m shares (these numbers exclude potential warrant and option conversion). The 'new' shareholders would own 23.5% of the enlarged issued share capital.

Effect on book value
Pro-forma September year end book value would improve from an estimated C$777k to C$2.8m and total assets increase from C$3.1m to C$5.1m.

The estimated book value per share and total assets per share are C$0.021 and C$0.039, respectively. The new price to book value would be 3.1 x

It should be noted that if there is no further equity raised, estimated 30 September 2009 year end undiluted book value would amount to only C$0.008 per share with total assets of C$0.031 per share. Estimated current undiluted price to book ratio is therefore 8.4 x.

Effect on earnings
Assuming that the company will now be in a position to successfully convert its project pipeline as per our core estimate, the new PER ratios for 2010, 2011 and 2012 are 350.6x, 7.9x and 4.0x respectively.

The reason the PER is so high in 2010 (despite a more than doubling in estimated turnover) is that because of the company's cost structure, reported profit will be small; accordingly, meaningful profit is likely to be deferred until the following years.

SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE!

Objective, Independent, Experienced.
Research you can trust!

Yes! Subscribe me for the latest stock research from Objective.
Email address
My Password
My information:
First Name
Family Name
Title:
Job title:
Job function:
Industry:
I am a:
 
To receive occasional printed reports complete your mailing address:
 
Company Name (if any)
Address
 
 
City
Postcode/Zip
Country

Please Read Objective's Terms of Use.


Balkan Resources (Private) - exploring the Perlati copper deposit in Albania
Oct 09, 2009 | Previous Reports

Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success
Sep 08, 2009 | Previous Reports

Sofame Technologies (SDW.V) - ambitious, but high risk growth strategy
Aug 24, 2009 | Previous Reports

Soho Resources (SOH.V) - substantial upgrade to total resource
Aug 19, 2009 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008 | Previous Reports

Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy
Nov 07, 2008 | Previous Reports

LiDCO (LID.L) - half year results show early signs of being on track
Oct 30, 2008 | Previous Reports

OCCASIONAL PAPERS

Albania - revisting old frontiers
October, 2008

The rise of independent research (IR Magazine)
March, 2006

Presentation to 2005 AIM Conference
Sept 26, 2005

The Role of Sponsored Research
June 22, 2005

Objective's Corporate Brochure
July 01, 2004

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839

About Us | Contact Us
Latest Analysis | Register Free | Archives
 
Copyright 2004 Objective Capital. All rights reserved.
Terms of Use | Privacy Policy | Disclaimer